Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Publication Month: Feb 2023 | No. of Pages: 121 Published By: Global Info Research
Single User License: US $ 3480
Corporate User License: US $ 6960

According to our (Global Info Research) latest study, the global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market size and forecasts, in consumption value ($ Million), sales quantity (K L), and average selling prices (US$/L), 2018-2029
Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K L), and average selling prices (US$/L), 2018-2029
Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K L), and average selling prices (US$/L), 2018-2029
Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market shares of main players, shipments in revenue ($ Million), sales quantity (K L), and ASP (US$/L), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abbott, Amgen, Arven Pharmaceuticals, Biocon and Cadila Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Vials
Prefilled
Market segment by Application
Myelosuppressive Chemotherapy
Leukemia Chemotherapy
Others
Major players covered
Abbott
Amgen
Arven Pharmaceuticals
Biocon
Cadila Pharmaceuticals
Dr.Reddy's Laboratories
Emcure Pharmaceuticals
Intas Pharmaceuticals
Kyowa Kirin
Novartis
Pfizer
Reliance Life Sciences
Harbin Pharmaceutical
North China Pharmaceutical
Jiuyuan Gene
Kexing Biopharm
Qilu Pharmaceutical
Quangang Pharmaceutical
Sunway Biotech
SL Pharmaceutical
Four Rings Bio-Pharmaceutical
Amoytop
Wuzhong Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF), with price, sales, revenue and global market share of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) from 2018 to 2023.
Chapter 3, the Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF).
Chapter 14 and 15, to describe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) sales channel, distributors, customers, research findings and conclusion.

1 Market Overview
1.1 Product Overview and Scope of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF)
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Vials
1.3.3 Prefilled
1.4 Market Analysis by Application
1.4.1 Overview: Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Myelosuppressive Chemotherapy
1.4.3 Leukemia Chemotherapy
1.4.4 Others
1.5 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size & Forecast
1.5.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (2018-2029)
1.5.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Abbott
2.1.1 Abbott Details
2.1.2 Abbott Major Business
2.1.3 Abbott Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.1.4 Abbott Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Abbott Recent Developments/Updates
2.2 Amgen
2.2.1 Amgen Details
2.2.2 Amgen Major Business
2.2.3 Amgen Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.2.4 Amgen Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Amgen Recent Developments/Updates
2.3 Arven Pharmaceuticals
2.3.1 Arven Pharmaceuticals Details
2.3.2 Arven Pharmaceuticals Major Business
2.3.3 Arven Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.3.4 Arven Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Arven Pharmaceuticals Recent Developments/Updates
2.4 Biocon
2.4.1 Biocon Details
2.4.2 Biocon Major Business
2.4.3 Biocon Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.4.4 Biocon Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Biocon Recent Developments/Updates
2.5 Cadila Pharmaceuticals
2.5.1 Cadila Pharmaceuticals Details
2.5.2 Cadila Pharmaceuticals Major Business
2.5.3 Cadila Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.5.4 Cadila Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Cadila Pharmaceuticals Recent Developments/Updates
2.6 Dr.Reddy's Laboratories
2.6.1 Dr.Reddy's Laboratories Details
2.6.2 Dr.Reddy's Laboratories Major Business
2.6.3 Dr.Reddy's Laboratories Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.6.4 Dr.Reddy's Laboratories Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Dr.Reddy's Laboratories Recent Developments/Updates
2.7 Emcure Pharmaceuticals
2.7.1 Emcure Pharmaceuticals Details
2.7.2 Emcure Pharmaceuticals Major Business
2.7.3 Emcure Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.7.4 Emcure Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Emcure Pharmaceuticals Recent Developments/Updates
2.8 Intas Pharmaceuticals
2.8.1 Intas Pharmaceuticals Details
2.8.2 Intas Pharmaceuticals Major Business
2.8.3 Intas Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.8.4 Intas Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Intas Pharmaceuticals Recent Developments/Updates
2.9 Kyowa Kirin
2.9.1 Kyowa Kirin Details
2.9.2 Kyowa Kirin Major Business
2.9.3 Kyowa Kirin Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.9.4 Kyowa Kirin Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Kyowa Kirin Recent Developments/Updates
2.10 Novartis
2.10.1 Novartis Details
2.10.2 Novartis Major Business
2.10.3 Novartis Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.10.4 Novartis Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Novartis Recent Developments/Updates
2.11 Pfizer
2.11.1 Pfizer Details
2.11.2 Pfizer Major Business
2.11.3 Pfizer Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.11.4 Pfizer Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Pfizer Recent Developments/Updates
2.12 Reliance Life Sciences
2.12.1 Reliance Life Sciences Details
2.12.2 Reliance Life Sciences Major Business
2.12.3 Reliance Life Sciences Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.12.4 Reliance Life Sciences Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Reliance Life Sciences Recent Developments/Updates
2.13 Harbin Pharmaceutical
2.13.1 Harbin Pharmaceutical Details
2.13.2 Harbin Pharmaceutical Major Business
2.13.3 Harbin Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.13.4 Harbin Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Harbin Pharmaceutical Recent Developments/Updates
2.14 North China Pharmaceutical
2.14.1 North China Pharmaceutical Details
2.14.2 North China Pharmaceutical Major Business
2.14.3 North China Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.14.4 North China Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 North China Pharmaceutical Recent Developments/Updates
2.15 Jiuyuan Gene
2.15.1 Jiuyuan Gene Details
2.15.2 Jiuyuan Gene Major Business
2.15.3 Jiuyuan Gene Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.15.4 Jiuyuan Gene Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Jiuyuan Gene Recent Developments/Updates
2.16 Kexing Biopharm
2.16.1 Kexing Biopharm Details
2.16.2 Kexing Biopharm Major Business
2.16.3 Kexing Biopharm Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.16.4 Kexing Biopharm Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Kexing Biopharm Recent Developments/Updates
2.17 Qilu Pharmaceutical
2.17.1 Qilu Pharmaceutical Details
2.17.2 Qilu Pharmaceutical Major Business
2.17.3 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.17.4 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Qilu Pharmaceutical Recent Developments/Updates
2.18 Quangang Pharmaceutical
2.18.1 Quangang Pharmaceutical Details
2.18.2 Quangang Pharmaceutical Major Business
2.18.3 Quangang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.18.4 Quangang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Quangang Pharmaceutical Recent Developments/Updates
2.19 Sunway Biotech
2.19.1 Sunway Biotech Details
2.19.2 Sunway Biotech Major Business
2.19.3 Sunway Biotech Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.19.4 Sunway Biotech Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.19.5 Sunway Biotech Recent Developments/Updates
2.20 SL Pharmaceutical
2.20.1 SL Pharmaceutical Details
2.20.2 SL Pharmaceutical Major Business
2.20.3 SL Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.20.4 SL Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.20.5 SL Pharmaceutical Recent Developments/Updates
2.21 Four Rings Bio-Pharmaceutical
2.21.1 Four Rings Bio-Pharmaceutical Details
2.21.2 Four Rings Bio-Pharmaceutical Major Business
2.21.3 Four Rings Bio-Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.21.4 Four Rings Bio-Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.21.5 Four Rings Bio-Pharmaceutical Recent Developments/Updates
2.22 Amoytop
2.22.1 Amoytop Details
2.22.2 Amoytop Major Business
2.22.3 Amoytop Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.22.4 Amoytop Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.22.5 Amoytop Recent Developments/Updates
2.23 Wuzhong Pharmaceutical
2.23.1 Wuzhong Pharmaceutical Details
2.23.2 Wuzhong Pharmaceutical Major Business
2.23.3 Wuzhong Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
2.23.4 Wuzhong Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.23.5 Wuzhong Pharmaceutical Recent Developments/Updates
3 Competitive Environment: Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) by Manufacturer
3.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Manufacturer (2018-2023)
3.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Manufacturer (2018-2023)
3.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturer Market Share in 2022
3.4.2 Top 6 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturer Market Share in 2022
3.5 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market: Overall Company Footprint Analysis
3.5.1 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market: Region Footprint
3.5.2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market: Company Product Type Footprint
3.5.3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Region
4.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Region (2018-2029)
4.1.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Region (2018-2029)
4.1.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price by Region (2018-2029)
4.2 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value (2018-2029)
4.3 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value (2018-2029)
4.4 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value (2018-2029)
4.5 South America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value (2018-2029)
4.6 Middle East and Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2018-2029)
5.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Type (2018-2029)
5.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2018-2029)
6.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Application (2018-2029)
6.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price by Application (2018-2029)
7 North America
7.1 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2018-2029)
7.2 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2018-2029)
7.3 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Country
7.3.1 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Country (2018-2029)
7.3.2 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2018-2029)
8.2 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2018-2029)
8.3 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Country
8.3.1 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Country (2018-2029)
8.3.2 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Region
9.3.1 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2018-2029)
10.2 South America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2018-2029)
10.3 South America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Country
10.3.1 South America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Country (2018-2029)
10.3.2 South America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Country
11.3.1 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Drivers
12.2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Restraints
12.3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) and Key Manufacturers
13.2 Manufacturing Costs Percentage of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF)
13.3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Production Process
13.4 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Typical Distributors
14.3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

Tables and Figures

List of Tables
Table 1. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Abbott Basic Information, Manufacturing Base and Competitors
Table 4. Abbott Major Business
Table 5. Abbott Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 6. Abbott Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Abbott Recent Developments/Updates
Table 8. Amgen Basic Information, Manufacturing Base and Competitors
Table 9. Amgen Major Business
Table 10. Amgen Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 11. Amgen Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Amgen Recent Developments/Updates
Table 13. Arven Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 14. Arven Pharmaceuticals Major Business
Table 15. Arven Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 16. Arven Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Arven Pharmaceuticals Recent Developments/Updates
Table 18. Biocon Basic Information, Manufacturing Base and Competitors
Table 19. Biocon Major Business
Table 20. Biocon Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 21. Biocon Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Biocon Recent Developments/Updates
Table 23. Cadila Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 24. Cadila Pharmaceuticals Major Business
Table 25. Cadila Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 26. Cadila Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Cadila Pharmaceuticals Recent Developments/Updates
Table 28. Dr.Reddy's Laboratories Basic Information, Manufacturing Base and Competitors
Table 29. Dr.Reddy's Laboratories Major Business
Table 30. Dr.Reddy's Laboratories Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 31. Dr.Reddy's Laboratories Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Dr.Reddy's Laboratories Recent Developments/Updates
Table 33. Emcure Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 34. Emcure Pharmaceuticals Major Business
Table 35. Emcure Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 36. Emcure Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Emcure Pharmaceuticals Recent Developments/Updates
Table 38. Intas Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 39. Intas Pharmaceuticals Major Business
Table 40. Intas Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 41. Intas Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Intas Pharmaceuticals Recent Developments/Updates
Table 43. Kyowa Kirin Basic Information, Manufacturing Base and Competitors
Table 44. Kyowa Kirin Major Business
Table 45. Kyowa Kirin Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 46. Kyowa Kirin Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Kyowa Kirin Recent Developments/Updates
Table 48. Novartis Basic Information, Manufacturing Base and Competitors
Table 49. Novartis Major Business
Table 50. Novartis Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 51. Novartis Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Novartis Recent Developments/Updates
Table 53. Pfizer Basic Information, Manufacturing Base and Competitors
Table 54. Pfizer Major Business
Table 55. Pfizer Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 56. Pfizer Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Pfizer Recent Developments/Updates
Table 58. Reliance Life Sciences Basic Information, Manufacturing Base and Competitors
Table 59. Reliance Life Sciences Major Business
Table 60. Reliance Life Sciences Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 61. Reliance Life Sciences Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Reliance Life Sciences Recent Developments/Updates
Table 63. Harbin Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 64. Harbin Pharmaceutical Major Business
Table 65. Harbin Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 66. Harbin Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Harbin Pharmaceutical Recent Developments/Updates
Table 68. North China Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 69. North China Pharmaceutical Major Business
Table 70. North China Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 71. North China Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. North China Pharmaceutical Recent Developments/Updates
Table 73. Jiuyuan Gene Basic Information, Manufacturing Base and Competitors
Table 74. Jiuyuan Gene Major Business
Table 75. Jiuyuan Gene Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 76. Jiuyuan Gene Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Jiuyuan Gene Recent Developments/Updates
Table 78. Kexing Biopharm Basic Information, Manufacturing Base and Competitors
Table 79. Kexing Biopharm Major Business
Table 80. Kexing Biopharm Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 81. Kexing Biopharm Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 82. Kexing Biopharm Recent Developments/Updates
Table 83. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 84. Qilu Pharmaceutical Major Business
Table 85. Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 86. Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 87. Qilu Pharmaceutical Recent Developments/Updates
Table 88. Quangang Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 89. Quangang Pharmaceutical Major Business
Table 90. Quangang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 91. Quangang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 92. Quangang Pharmaceutical Recent Developments/Updates
Table 93. Sunway Biotech Basic Information, Manufacturing Base and Competitors
Table 94. Sunway Biotech Major Business
Table 95. Sunway Biotech Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 96. Sunway Biotech Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 97. Sunway Biotech Recent Developments/Updates
Table 98. SL Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 99. SL Pharmaceutical Major Business
Table 100. SL Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 101. SL Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 102. SL Pharmaceutical Recent Developments/Updates
Table 103. Four Rings Bio-Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 104. Four Rings Bio-Pharmaceutical Major Business
Table 105. Four Rings Bio-Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 106. Four Rings Bio-Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Four Rings Bio-Pharmaceutical Recent Developments/Updates
Table 108. Amoytop Basic Information, Manufacturing Base and Competitors
Table 109. Amoytop Major Business
Table 110. Amoytop Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 111. Amoytop Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 112. Amoytop Recent Developments/Updates
Table 113. Wuzhong Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 114. Wuzhong Pharmaceutical Major Business
Table 115. Wuzhong Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product and Services
Table 116. Wuzhong Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (K L), Average Price (US$/L), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 117. Wuzhong Pharmaceutical Recent Developments/Updates
Table 118. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Manufacturer (2018-2023) & (K L)
Table 119. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Manufacturer (2018-2023) & (USD Million)
Table 120. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price by Manufacturer (2018-2023) & (US$/L)
Table 121. Market Position of Manufacturers in Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF), (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 122. Head Office and Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Production Site of Key Manufacturer
Table 123. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market: Company Product Type Footprint
Table 124. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market: Company Product Application Footprint
Table 125. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) New Market Entrants and Barriers to Market Entry
Table 126. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Mergers, Acquisition, Agreements, and Collaborations
Table 127. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Region (2018-2023) & (K L)
Table 128. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Region (2024-2029) & (K L)
Table 129. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Region (2018-2023) & (USD Million)
Table 130. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Region (2024-2029) & (USD Million)
Table 131. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price by Region (2018-2023) & (US$/L)
Table 132. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price by Region (2024-2029) & (US$/L)
Table 133. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2018-2023) & (K L)
Table 134. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2024-2029) & (K L)
Table 135. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Type (2018-2023) & (USD Million)
Table 136. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Type (2024-2029) & (USD Million)
Table 137. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price by Type (2018-2023) & (US$/L)
Table 138. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price by Type (2024-2029) & (US$/L)
Table 139. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2018-2023) & (K L)
Table 140. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2024-2029) & (K L)
Table 141. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Application (2018-2023) & (USD Million)
Table 142. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Application (2024-2029) & (USD Million)
Table 143. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price by Application (2018-2023) & (US$/L)
Table 144. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price by Application (2024-2029) & (US$/L)
Table 145. North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2018-2023) & (K L)
Table 146. North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2024-2029) & (K L)
Table 147. North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2018-2023) & (K L)
Table 148. North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2024-2029) & (K L)
Table 149. North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Country (2018-2023) & (K L)
Table 150. North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Country (2024-2029) & (K L)
Table 151. North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Country (2018-2023) & (USD Million)
Table 152. North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Country (2024-2029) & (USD Million)
Table 153. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2018-2023) & (K L)
Table 154. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2024-2029) & (K L)
Table 155. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2018-2023) & (K L)
Table 156. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2024-2029) & (K L)
Table 157. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Country (2018-2023) & (K L)
Table 158. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Country (2024-2029) & (K L)
Table 159. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Country (2018-2023) & (USD Million)
Table 160. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Country (2024-2029) & (USD Million)
Table 161. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2018-2023) & (K L)
Table 162. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2024-2029) & (K L)
Table 163. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2018-2023) & (K L)
Table 164. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2024-2029) & (K L)
Table 165. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Region (2018-2023) & (K L)
Table 166. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Region (2024-2029) & (K L)
Table 167. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Region (2018-2023) & (USD Million)
Table 168. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Region (2024-2029) & (USD Million)
Table 169. South America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2018-2023) & (K L)
Table 170. South America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2024-2029) & (K L)
Table 171. South America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2018-2023) & (K L)
Table 172. South America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2024-2029) & (K L)
Table 173. South America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Country (2018-2023) & (K L)
Table 174. South America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Country (2024-2029) & (K L)
Table 175. South America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Country (2018-2023) & (USD Million)
Table 176. South America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Country (2024-2029) & (USD Million)
Table 177. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2018-2023) & (K L)
Table 178. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Type (2024-2029) & (K L)
Table 179. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2018-2023) & (K L)
Table 180. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Application (2024-2029) & (K L)
Table 181. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Region (2018-2023) & (K L)
Table 182. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity by Region (2024-2029) & (K L)
Table 183. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Region (2018-2023) & (USD Million)
Table 184. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Region (2024-2029) & (USD Million)
Table 185. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Raw Material
Table 186. Key Manufacturers of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Raw Materials
Table 187. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Typical Distributors
Table 188. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Typical Customers
List of Figures
Figure 1. Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Picture
Figure 2. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value Market Share by Type in 2022
Figure 4. Vials Examples
Figure 5. Prefilled Examples
Figure 6. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value Market Share by Application in 2022
Figure 8. Myelosuppressive Chemotherapy Examples
Figure 9. Leukemia Chemotherapy Examples
Figure 10. Others Examples
Figure 11. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity (2018-2029) & (K L)
Figure 14. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price (2018-2029) & (US$/L)
Figure 15. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity Market Share by Manufacturer in 2022
Figure 16. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value Market Share by Manufacturer in 2022
Figure 17. Producer Shipments of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 18. Top 3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Top 6 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity Market Share by Region (2018-2029)
Figure 21. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value Market Share by Region (2018-2029)
Figure 22. North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value (2018-2029) & (USD Million)
Figure 23. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value (2018-2029) & (USD Million)
Figure 24. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value (2018-2029) & (USD Million)
Figure 25. South America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value (2018-2029) & (USD Million)
Figure 26. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value (2018-2029) & (USD Million)
Figure 27. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity Market Share by Type (2018-2029)
Figure 28. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value Market Share by Type (2018-2029)
Figure 29. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price by Type (2018-2029) & (US$/L)
Figure 30. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity Market Share by Application (2018-2029)
Figure 31. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value Market Share by Application (2018-2029)
Figure 32. Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price by Application (2018-2029) & (US$/L)
Figure 33. North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity Market Share by Type (2018-2029)
Figure 34. North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity Market Share by Application (2018-2029)
Figure 35. North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity Market Share by Country (2018-2029)
Figure 36. North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value Market Share by Country (2018-2029)
Figure 37. United States Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Canada Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Mexico Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity Market Share by Type (2018-2029)
Figure 41. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity Market Share by Application (2018-2029)
Figure 42. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity Market Share by Country (2018-2029)
Figure 43. Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value Market Share by Country (2018-2029)
Figure 44. Germany Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. France Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. United Kingdom Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Russia Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Italy Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity Market Share by Type (2018-2029)
Figure 50. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity Market Share by Application (2018-2029)
Figure 51. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Quantity Market Share by Region (2018-2029)
Figure 52. Asia-Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value Market Share by Region (2018-2029)
Figure 53. China Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Japan Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Korea Recombinant Human Granulocyte Colony-Stimulating F



Companies Mentioned
Abbott
Amgen
Arven Pharmaceuticals
Biocon
Cadila Pharmaceuticals
Dr.Reddy's Laboratories
Emcure Pharmaceuticals
Intas Pharmaceuticals
Kyowa Kirin
Novartis
Pfizer
Reliance Life Sciences
Harbin Pharmaceutical
North China Pharmaceutical
Jiuyuan Gene
Kexing Biopharm
Qilu Pharmaceutical
Quangang Pharmaceutical
Sunway Biotech
SL Pharmaceutical
Four Rings Bio-Pharmaceutical
Amoytop
Wuzhong Pharmaceutical

Reason to Buy

  • Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The segment that is expected to dominate the Pharma & Healthcare Market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets